These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
139 related items for PubMed ID: 9863160
1. Pharmacokinetics of weekly transdermal estradiol controlled delivery system in postmenopausal Chinese. Chen GS, Zhang MY, Wang Q, Ye JC. Zhongguo Yao Li Xue Bao; 1996 Sep; 17(5):407-10. PubMed ID: 9863160 [Abstract] [Full Text] [Related]
2. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol. Setnikar I, Rovati LC, Vens-Cappell B, Hilgenstock C. Arzneimittelforschung; 1996 Aug; 46(8):766-73. PubMed ID: 9125276 [Abstract] [Full Text] [Related]
3. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Scott RT, Ross B, Anderson C, Archer DF. Obstet Gynecol; 1991 May; 77(5):758-64. PubMed ID: 2014092 [Abstract] [Full Text] [Related]
4. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix. Setnikar I, Rovati LC, Vens-Cappell B, Hilgenstock C. Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686 [Abstract] [Full Text] [Related]
5. Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara. Buch A, Shen L, Kelly S, Sahota R, Brezovic C, Bixler C, Powell J. Menopause; 1998 Mar; 5(2):107-12. PubMed ID: 9689205 [Abstract] [Full Text] [Related]
6. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women. Rohr UD, Nauert C, Stehle B. Maturitas; 1999 Sep 24; 33(1):45-58. PubMed ID: 10585173 [Abstract] [Full Text] [Related]
7. [Bioavailability of 17 beta-estradiol after transdermal administration--dependence on the patch system]. Schmolling J, Kusche J, van der Ven H, Schander K. Zentralbl Gynakol; 1998 Sep 24; 120(3):121-5. PubMed ID: 9556902 [Abstract] [Full Text] [Related]
8. Plasma profiles of transdermal 17 beta-estradiol delivered by two different matrix patches. A four-way cross-over study in postmenopausal women. Rohr UD, Ehrly AM, Kuhl H. Arzneimittelforschung; 1997 Jun 24; 47(6):761-7. PubMed ID: 9239456 [Abstract] [Full Text] [Related]
9. Bioavailability of estradiol from two transdermal patches. Setnikar I, Rovati LC, Vens-Cappell B, Hilgenstock C. Arzneimittelforschung; 1996 Mar 24; 46(3):307-10. PubMed ID: 8901155 [Abstract] [Full Text] [Related]
10. Steady-state pharmacokinetics following application of a novel transdermal estradiol spray in healthy postmenopausal women. Morton TL, Gattermeir DJ, Petersen CA, Day WW, Schumacher RJ. J Clin Pharmacol; 2009 Sep 24; 49(9):1037-46. PubMed ID: 19628730 [Abstract] [Full Text] [Related]
11. [Transdermal estradiol--the possibility for replacement therapy in the postmenopause]. Rachev E. Akush Ginekol (Sofiia); 1994 Sep 24; 33(3):45-7. PubMed ID: 7793531 [Abstract] [Full Text] [Related]
12. Characterization of a 7 day 17 beta-estradiol transdermal delivery system: pharmacokinetics in healthy postmenopausal women. Boyd RA, Zegarac EA, Eldon MA, Sedman AJ, Forgue ST. Biopharm Drug Dispos; 1996 Aug 24; 17(6):459-70. PubMed ID: 8866037 [Abstract] [Full Text] [Related]
13. Pharmacokinetics of continuous once-a-week combination 17β-Estradiol/Low- or high-dose levonorgestrel transdermal delivery systems in postmenopausal women. Karara AH, Harrison LI, Melikian AP, Poola N, Morrison D, Bourg D, Bourg L, Zurth C. J Clin Pharmacol; 2014 May 24; 54(5):520-7. PubMed ID: 24474034 [Abstract] [Full Text] [Related]
14. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status. Gupta P, Ozel B, Stanczyk FZ, Felix JC, Mishell DR. Menopause; 2008 May 24; 15(1):94-7. PubMed ID: 17882008 [Abstract] [Full Text] [Related]
15. Use of transdermal oestradiol (Estraderm TTS) in hypertensive postmenopausal women. Foidart JM. Br J Clin Pract Suppl; 1996 Sep 24; 86():14-6. PubMed ID: 8995005 [No Abstract] [Full Text] [Related]
16. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women. Samsioe G, Dvorak V, Genazzani AR, Hamann B, Heikkinen J, Mueck AO, Suzin J, Kawakami FT, Ferreira A, Sun D, Arguinzoniz M. Maturitas; 2007 Jun 20; 57(2):171-81. PubMed ID: 17317046 [Abstract] [Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women. Karara AH, Hanes V, Alonso A, Ni P, Poola N, Silang R, Blode H, Preston RA. J Clin Pharmacol; 2007 Oct 20; 47(10):1292-302. PubMed ID: 17906162 [Abstract] [Full Text] [Related]
18. Comparison of pharmacokinetic profiles of a 17 beta-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state. Paoletti AM, Pilia I, Nannipieri F, Bigini C, Melis GB. Maturitas; 2001 Dec 14; 40(3):203-9. PubMed ID: 11731181 [Abstract] [Full Text] [Related]
19. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. Mueck AO, Genazzani AR, Samsioe G, Vukovic-Wysocki I, Seeger H. Menopause; 2007 Dec 14; 14(6):978-84. PubMed ID: 17595593 [Abstract] [Full Text] [Related]
20. Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice. Henzl MR, Loomba PK. J Reprod Med; 2003 Jul 14; 48(7):525-40. PubMed ID: 12953327 [Abstract] [Full Text] [Related] Page: [Next] [New Search]